Your browser doesn't support javascript.
loading
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie, Claire; Dias, Juliana; O'Reilly, Maeve A; Abbasian, Mahnaz; Cadinanos-Garai, Amaia; Vispute, Ketki; Bosshard-Carter, Leticia; Mitsikakou, Marina; Mehra, Vedika; Roddy, Harriet; Hartley, John A; Spanswick, Victoria; Lowe, Helen; Popova, Bilyana; Clifton-Hadley, Laura; Wheeler, Graham; Olejnik, Joanna; Bloor, Adrian; Irvine, David; Wood, Leigh; Marzolini, Maria A V; Domning, Sabine; Farzaneh, Farzin; Lowdell, Mark W; Linch, David C; Pule, Martin A; Peggs, Karl S.
Afiliação
  • Roddie C; Cancer Institute, University College London, London, United Kingdom.
  • Dias J; Department of Haematology, UCLH, London, United Kingdom.
  • O'Reilly MA; Cancer Institute, University College London, London, United Kingdom.
  • Abbasian M; Royal Free Hospital London, NHS Foundation Trust, London, United Kingdom.
  • Cadinanos-Garai A; Department of Haematology, UCLH, London, United Kingdom.
  • Vispute K; Cancer Institute, University College London, London, United Kingdom.
  • Bosshard-Carter L; Cancer Institute, University College London, London, United Kingdom.
  • Mitsikakou M; Cancer Institute, University College London, London, United Kingdom.
  • Mehra V; Cancer Institute, University College London, London, United Kingdom.
  • Roddy H; Cancer Institute, University College London, London, United Kingdom.
  • Hartley JA; Cancer Institute, University College London, London, United Kingdom.
  • Spanswick V; Cancer Institute, University College London, London, United Kingdom.
  • Lowe H; Cancer Institute, University College London, London, United Kingdom.
  • Popova B; UCL Experimental Cancer Medicine Centre Good Clinical Laboratory Practice Facility, London, United Kingdom.
  • Clifton-Hadley L; Cancer Institute, University College London, London, United Kingdom.
  • Wheeler G; UCL Experimental Cancer Medicine Centre Good Clinical Laboratory Practice Facility, London, United Kingdom.
  • Olejnik J; Cancer Institute, University College London, London, United Kingdom.
  • Bloor A; UCL Experimental Cancer Medicine Centre Good Clinical Laboratory Practice Facility, London, United Kingdom.
  • Irvine D; CRUK UCL Cancer Trials Centre, London, United Kingdom.
  • Wood L; CRUK UCL Cancer Trials Centre, London, United Kingdom.
  • Marzolini MAV; CRUK UCL Cancer Trials Centre, London, United Kingdom.
  • Domning S; Current address: Imperial Clinical Trials Unit, Imperial College London, London, United Kingdom.
  • Farzaneh F; CRUK UCL Cancer Trials Centre, London, United Kingdom.
  • Lowdell MW; The Christie Hospital, Manchester, United Kingdom.
  • Linch DC; Queen Elizabeth University Hospital, Glasgow, Scotland.
  • Pule MA; Department of Haematology, UCLH, London, United Kingdom.
  • Peggs KS; Department of Haematology, UCLH, London, United Kingdom.
J Clin Oncol ; 39(30): 3352-3363, 2021 10 20.
Article em En | MEDLINE | ID: mdl-34464155

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Antígenos CD19 / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Antígenos CD19 / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido